SY-201 / Seinda Pharma - LARVOL DELTA

A Phase 2, Double-Masked, Randomized, Vehicle-controlled Trial of SY201 in Dry Eye Disease in US (ARVO 2025) - "What they really want are treatments that work faster and more effectively—ones that not only help their eyes feel better but also improve their vision. In its Phase 2 study, SY201 eye drops showed rapid and significant improvement in dry eye symptoms and overall eye surface health by repairing the eye surface and restoring its natural balance."

Clinical • P2 data • Dry Eye Disease • Ophthalmology • MMP9

SY201. Video Laryngoscopy, Exploring Patient Safety and Costs(non-CME) (ASA 2024) - "Adam Thaler will discuss evaluating VL products for cost-effectiveness and implementation in his practice. Medtronic, Corporate Supporter"

Clinical • Video • Anesthesia

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=201 | Completed | Sponsor: Seinda Pharmaceutical Guangzhou Corporation | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Mar 2023 | Trial primary completion date: Jul 2023 ➔ Mar 2023

Trial completion • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Seinda Pharmaceutical Guangzhou Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Dry Eye Disease • Ophthalmology

Double-masked Controlled Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=200 | Not yet recruiting | Sponsor: Seinda Pharmaceutical Guangzhou Corporation

New P1/2 trial • Dry Eye Disease • Ophthalmology